Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al
| Autor: | Hendrik Schulze-Koops, Klaus Krueger, Christof Specker |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Context (language use) General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Rheumatology Rheumatic Diseases Pandemic medicine Humans Immunology and Allergy Intensive care medicine Pandemics 030203 arthritis & rheumatology Antirheumatic therapy SARS-CoV-2 business.industry COVID-19 Immunosuppression Response to treatment Treatment Adherence and Compliance 030104 developmental biology Increased risk business |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2020-217987 |
| Popis: | We read with interest the study of Fragoulis et al 1 about treatment adherence and behaviour changes of patients with autoimmune inflammatory rheumatic diseases (AIRD) in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 pandemic. In their study, only 11 out of the 500 patients with AIRD interviewed had discontinued antirheumatic treatment solely due to fear of immunosuppression, for example, for fear of an increased risk for SARS-CoV-2 infection. This is reassuring to note as interruption of clinically efficacious therapy in AIRD is associated with an increased risk of relapse2 which might lead to the necessity of intensifying immunosuppressive therapy, possibly beyond the original level. For this very apprehension and also for the accumulating cautious impression that patients with rheumatological diseases might not have a worse prognosis during COVID-19,3 4 … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|